BIOHAVN PHRMCTCL

 BHVNのチャート


 BHVNの企業情報

symbol BHVN
会社名 Biohaven Pharmaceutical Holding Co Ltd (BIOHAVN PHRMCTCL)
分野(sector)   
産業(industry)   
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 バイオヘイヴン・ファーマスーティカル・ホールディング(Biohaven Pharmaceutical Holding Company Ltd.)は米国のバイオ医薬品会社である。同社はオーファン神経学的徴候と他の神経学的経路を標的とする臨床段階化合物の同定・開発に従事する。同社は複数の後期薬剤候補のポートフォリオを有する。同社のパイプラインはグルタミン酸調節剤の処方物であるBHV-0223、グルタミン酸を調節するニューケミカルエンティティ(NCE)であるBHV-4157、N-メチル-D-アスパラギン酸(NMDA)受容体拮抗作用を標的とする同社の治験代理人であるBHV-5000を含む。臨床化合物であるトリグリルゾールは神経変性疾患と癌の適応症等に適応される。同社のパイプラインにはBHV-3000とBHV-3500を含む。同社はオーファン・神経科学の適応症における他のメカニズム論的アプローチを進めることに焦点を当て、追加の化合物ライセンスを探査する。  バイオヘイブン・ファ―マシュ―ティカル・ホ―ルディングはイギリス領ヴァ―ジン諸島籍の医薬品メ―カ―持株会社。子会社を通じて、希少疾病を含む神経系疾患の治療薬の開発に従事する。主な候補薬には、片頭痛の急性治療薬「Rimegepant」や脊髄小脳失調症の治療を対象とする「Trigriluzole」がある。本社はコネチカット州ニュ―ヘイブン。  
本社所在地 c/o Biohaven Pharmaceuticals Inc. 215 Church Street New Haven CT 06510 USA
代表者氏名 Declan Doogan
代表者役職名 Independent Chairman of the Board
電話番号 +1 203-404-0410
設立年月日 41518
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 63人
url www.biohavenpharma.com
nasdaq_url
adr_tso
EBITDA (百万ドル) -224.53700
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 2221.54300
売上高 (百万ドル) 0.00000
企業価値(EV) (百万ドル) 1957.29400
当期純利益 (百万ドル) -240.92200
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Biohaven Pharmaceutical Holding Co Ltd revenues was not reported. Net loss applicable to common stockholders increased 73% to $240.9M. Higher net loss reflects Research and development - Balancing val increase from $82.5M to $181.6M (expense) General and administrative - Balancing v increase from $11.8M to $26M (expense) Stock-based Compensation in SGA increase of 36% to $8.6M (expense).

 BHVNのテクニカル分析


 BHVNのニュース

   Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares  2021/03/16 02:16:00 PR Newswire
NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting…
   Biohaven Announces Proposed Public Offering Of Common Shares  2021/03/15 20:32:00 PR Newswire
NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting…
   Biohaven's NURTEC® ODT Approved In Israel For Acute Treatment Of Migraine  2021/03/10 12:30:00 PR Newswire
NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and Medison Pharma announced today that NURTEC® ODT (rimegepant) was approved by the Israeli Ministry of Health for the acute treatment of migraine with and without aura…
   Leerink Partners Stick to Their Buy Rating for Biohaven Pharmaceutical Holding Co Ltd By Investing.com  2021/03/02 14:48:16 Investing.com
Leerink Partners Stick to Their Buy Rating for Biohaven Pharmaceutical Holding Co Ltd
   Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments  2021/03/01 12:30:00 PR Newswire
NEW HAVEN, Conn., March 1, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including…
   Biohaven Pharmaceutical (NYSE:BHVN) Price Target Raised to $110.00  2020/11/20 07:54:43 Transcript Daily
Biohaven Pharmaceutical (NYSE:BHVN) had its price target boosted by Canaccord Genuity from $80.00 to $110.00 in a research report report published on Monday, The Fly reports. They currently have a buy rating on the stock. A number of other research analysts also recently weighed in on the stock. Wedbush upped their price objective on shares […]
   Recap: Biohaven Pharmaceutical Q3 Earnings  2020/11/09 08:32:00 Benzinga
Shares of Biohaven Pharmaceutical (NYSE:BHVN) traded flat in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per …
   Gregory Bailey Sells 3,748 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock  2020/10/23 02:18:45 Daily Political
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 3,748 shares of Biohaven Pharmaceutical stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $78.88, for a total transaction of $295,642.24. Following the sale, the director now owns 2,585,181 shares in the company, valued at $203,919,077.28. The […]
   Gregory Bailey Sells 4,554 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock  2020/10/21 22:42:45 US Banking News
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 4,554 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $78.98, for a total value of $359,674.92. Following the completion of the sale, the director now directly owns 2,585,181 shares in […]
   Biohaven Pharmaceutical : 2Q Earnings 2020 | MarketScreener  2020/08/10 13:44:07 MarketScreener
2nd Quarter 2020 Earnings August 10, 2020 Ellie, living with migraine … | August 10, 2020
   Biohaven Pharmaceutical (NYSE:BHVN) Price Target Raised to $110.00  2020/11/20 07:54:43 Transcript Daily
Biohaven Pharmaceutical (NYSE:BHVN) had its price target boosted by Canaccord Genuity from $80.00 to $110.00 in a research report report published on Monday, The Fly reports. They currently have a buy rating on the stock. A number of other research analysts also recently weighed in on the stock. Wedbush upped their price objective on shares […]
   Recap: Biohaven Pharmaceutical Q3 Earnings  2020/11/09 08:32:00 Benzinga
Shares of Biohaven Pharmaceutical (NYSE:BHVN) traded flat in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per …
   Gregory Bailey Sells 3,748 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock  2020/10/23 02:18:45 Daily Political
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 3,748 shares of Biohaven Pharmaceutical stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $78.88, for a total transaction of $295,642.24. Following the sale, the director now owns 2,585,181 shares in the company, valued at $203,919,077.28. The […]
   Gregory Bailey Sells 4,554 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock  2020/10/21 22:42:45 US Banking News
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 4,554 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $78.98, for a total value of $359,674.92. Following the completion of the sale, the director now directly owns 2,585,181 shares in […]
   Biohaven Pharmaceutical : 2Q Earnings 2020 | MarketScreener  2020/08/10 13:44:07 MarketScreener
2nd Quarter 2020 Earnings August 10, 2020 Ellie, living with migraine … | August 10, 2020

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 BIOHAVN PHRMCTCL BHVN )

 twitter  (公式ツイッターやCEOツイッターなど)